In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease.

The researchers also noted that some newly approved monoclonal antibody treatments (aducanumab, lecanemab, and donanemab) unintentionally increased Aβ42 levels in cerebrospinal fluid, which ...

Like Aduhelm (aducanumab) lecanemab – also known as BAN2401 ... said it will seek accelerated FDA approval of its candidate donanemab later this year, based on the results of the phase ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based ... Eisai and Biogen's Leqembi (lecanemab) onto the US market ...

Lecanemab and donanemab received the green light from regulators last year but the benefits were deemed "too small to justify the costs" to the health service. Re:Cognition Health, based on Harley ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...